# A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

> **NCT01667133** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ariad Pharmaceuticals** · enrollment: 35 (actual)

## Conditions studied

- Chronic Myeloid Leukemia (CML)
- Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

## Interventions

- **DRUG:** ponatinib - Phase 1
- **DRUG:** ponatinib - Phase 2

## Key facts

- **NCT ID:** NCT01667133
- **Lead sponsor:** Ariad Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-31
- **Primary completion:** 2018-08-02
- **Final completion:** 2018-08-02
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01667133

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01667133, "A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01667133. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*